PubMed Health⌕ Search

Biomedical subjects

M Stannard

Publications and source records attributed to M Stannard.

At least 19 recordsLinked to original sources
PubMed1986

Indoramin in the hypertensive diabetic patient.

In 32 hypertensive diabetic patients a study was performed to determine the effects of indoramin on blood pressure and blood glucose, plasma insulin, C-peptide, serum total cholesterol, and triglyceride levels. All patients evaluated showed a significant fall in blood pressure with daily doses of 50 to 200 mg of indoramin. In six insulin-dependent diabetic patients there was no change in diabetic control and no effect on the incidence of hypoglycaemia. In 18 noninsulin-dependent diabetics monitored for 3 months and in 14 followed for 12 months, there was no significant change in glucose tolerance after a 75 g glucose dose; mean plasma C-peptide levels and 2 h insulin levels were increased at 12 months. Mean weight and mean fasting cholesterol and triglyceride concentrations were unchanged. Nine patients withdrew because of side effects, mainly drowsiness and lethargy.

Adolescent↗
PubMed1986

Antihypertensive therapy with indoramin: risk-benefit profile in clinical practice.

In a multicenter, prospective study of step II antihypertensive therapy with indoramin, 1,847 hypertensive patients (773 men and 1,074 women) between the ages of 18 and 70 years were treated by 148 general practitioners. Patients whose blood pressure was inadequately controlled after 4 weeks of therapy with cyclopenthiazide (0.25 to 1.0 mg/day) had indoramin (25 to 200 mg/day) added to their treatment regimen. During cyclopenthiazide treatment, mean (+/- SD) blood pressure decreased from 176/105 +/- 20/7 mm Hg at baseline to 164/98 +/- 21/9 mm Hg (p less than 0.001), and only 447 (24%) patients obtained satisfactory blood pressure control. The addition of indoramin produced a further reduction in mean blood pressure from 169/102 +/- 18/6 to 152/89 +/- 18/8 mm Hg during the first 3 months of treatment (p less than 0.001); this response was maintained for up to 2 years. Satisfactory blood pressure reduction was achieved in 79% of the patients who received indoramin (mean dose, 68 mg/day) plus cyclopenthiazide. Only 25 patients (2%) discontinued indoramin treatment because of nonresponse, and 156 (12%) withdrew because of adverse effects, the most common being sedation, dizziness/giddiness, and headache. These results indicate that indoramin provides safe and effective blood pressure control when used as step II treatment for hypertensive patients who fail to respond to single-agent diuretic therapy.

Adolescent↗
PubMed1982

A new pathway for repair of cross-linkable 8-methoxypsoralen mono-adducts in Uvr strains of Escherichia coli.

UvrA-deficient Escherichia coli bacteria possess a DNA repair pathway for certain photoinduced mono-adducts of 8-methoxypsoralen. Such adducts can be converted to highly lethal cross-links by a second exposure to near-UV light in the absence of 8-methoxypsoralen. If a period of incubation is allowed to intervene between the primary and cross-linking exposure, the lethal effect is considerably diminished, indicating that some of the mono-adducts become unavailable for cross-linking. A repair pathway is postulated which is pre-replicative, unaffected by chloramphenicol, acriflavine or caffeine, and inhibited at 0 degrees C. It is unaffected by a rep mutation but is blocked by a polA mutation, suggesting that it involves DNA strand breakage and at least some exonuclease action.

DNA Repair↗